1. Rockman CB, Maldonado TS, Jacobowitz GR, et al. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann Vasc Surg. 2012. 26:411–418.
2. Sator MO, Akramian J, Joura EA, et al. Reduction of intraocular pressure in a glaucoma patient undergoing hormone replacement therapy. Maturitas. 1998. 29:93–95.
3. Freeman EE, Munoz B, Schein OD, West SK. Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors. Epidemiology. 2004. 15:451–457.
4. Younan C, Mitchell P, Cumming RG, et al. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol. 2002. 155:997–1006.
5. Kanthan GL, Wang JJ, Burlutsky G, et al. Exogenous oestrogen exposure, female reproductive factors and the long-term incidence of cataract: the Blue Mountains Eye Study. Acta Ophthalmol. 2010. 88:773–778.
6. Klein BE, Klein R, Moss SE. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999. 22:1984–1987.
7. Erdem U, Muftuoglu O, Goktolga U, Dagli S. Effect of hormone replacement therapy in women on ocular refractive status and aberrations. J Refract Surg. 2007. 23:567–572.
8. Edwards DR, Gallins P, Polk M, et al. Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms. Invest Ophthalmol Vis Sci. 2010. 51:1873–1879.
9. Freeman EE, Munoz B, Bressler SB, West SK. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005. 12:37–45.
10. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997. 25:Suppl 1. S13–S15.
11. Erdem U, Ozdegirmenci O, Sobaci E, et al. Dry eye in post-menopausal women using hormone replacement therapy. Maturitas. 2007. 56:257–262.
12. Mathers WD, Dolney AM, Kraemer D. The effect of hormone replacement therapy on the symptoms and physiologic parameters of dry eye. Adv Exp Med Biol. 2002. 506:1017–1022.
13. Barney NP. Can hormone replacement therapy cause dry eye? Arch Ophthalmol. 2002. 120:641–642.
14. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001. 286:2114–2119.
15. Moon JH, Jung JW, Shin KH, Paik HJ. Effect of hormone replacement therapy on dry eye syndrome in postmenopausal women: A prospective study. J Korean Ophthalmol Soc. 2010. 51:175–179.
16. Yoon KC, Mun GH, Kim SD, et al. Prevalence of eye diseases in South Korea: data from the Korea national health and nutrition examination survey 2008-2009. Korean J Ophthalmol. 2011. 25:421–433.
17. Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010. 13:317–327.
18. Namkung J, Chung YJ, Ha JE, et al. The survey on Korean menopausal women's behavior and perception of hormone therapy. J Korean Soc Menopause. 2011. 17:142–149.
19. Maclennan AH, Wilson DH, Taylor AW. Hormone replacement therapy: Prevalence, compliance and the 'healthy women' notion. Climacteric. 1998. 1:42–49.
20. Connelly MT, Richardson M, Platt R. Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995. J Gen Intern Med. 2000. 15:542–550.
21. Sharma S, Rekha W, Sharma T, Downey G. Refractive issues in pregnancy. Aust N Z J Obstet Gynaecol. 2006. 46:186–188.
22. Affinito P, Di Spiezio Sardo A, Di Carlo C, et al. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause. 2003. 10:482–487.
23. Ishioka M, Shimmura S, Yagi Y, Tsubota K. Pterygium and dry eye. Ophthalmologica. 2001. 215:209–211.
24. Rajiv , Mithal S, Sood AK. Pterygium and dry eye--a clinical correlation. Indian J Ophthalmol. 1991. 39:15–16.
25. Glacet-Bernard A, Kuhn D, Soubrane G. Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy. Contracept Fertil Sex. 1999. 27:285–290.
26. Arroyo J. Age-related eye diseases: impact of hormone replacement therapy, and reproductive and other risk factors,. by K. K. Snow and J. M. Seddon. Int J Fertil Womens Med 45:301-13, 2000. Surv Ophthalmol. 2003. 48:236–237.
27. Sator MO, Joura EA, Frigo P, et al. Hormone replacement therapy and intraocular pressure. Maturitas. 1997. 28:55–58.
28. Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol. 2006. 22:501–505.